Latest & greatest articles for tiotropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tiotropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tiotropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tiotropium

21. Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment)

Tiotropium/olodaterol: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Tiotropium/Olodaterol – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-31 (...) Tiotropium/olodaterol – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-31 Version 1.0 Tiotropium/olodaterol – Benefit assessment acc. to §35a Social Code Book V 12 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tiotropium/olodaterol – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

Institute for Quality and Efficiency in Healthcare (IQWiG)2015

22. Tiotropium bromide

Tiotropium bromide Tiotropium bromide Tiotropium bromide CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tiotropium bromide. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Common Drug Review. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that tiotropium bromide (Spiriva

Health Technology Assessment (HTA) Database.2014

23. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a (...) systematic review and network meta-analysis Karabis A, Lindner L, Mocarski M, Huisman E, Greening A CRD summary This review of maintenance treatments for moderate-to-severe chronic obstructive pulmonary disease concluded that aclidinium, tiotropium and glycopyrronium were comparable and better than placebo with respect to improvements in lung function, health-related quality of life and dyspnoea at 12 and 24 week time points. The conclusions are moderately reliable with uncertainty relating to indirect

DARE.2013

24. Tiotropium Respimat inhaler and the risk of death in COPD.

Tiotropium Respimat inhaler and the risk of death in COPD. BACKGROUND: Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than (...) with placebo. METHODS: In this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 μg or 5 μg, as compared with tiotropium HandiHaler at a once-daily dose of 18 μg. Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 μg or 2.5 μg vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 μg vs. HandiHaler

NEJM2013

25. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. BACKGROUND: Combination therapy (inhaled corticosteroids and long-acting beta2-agonists) and tiotropium are both used in the treatment of chronic obstructive pulmonary disease (COPD). There is uncertainty about the relative benefits and harms of these treatments. OBJECTIVES: To compare the relative effects of inhaled combination therapy and tiotropium on markers (...) of exacerbations, symptoms, quality of life, lung function, pneumonia and serious adverse events in patients with chronic obstructive pulmonary disease. SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register of trials (November 2012) and reference lists of articles. We also contacted authors of the studies. SELECTION CRITERIA: We included only parallel, randomised controlled trials comparing inhaled combination corticosteroid and long-acting beta2-agonist against inhaled tiotropium bromide

Cochrane2013

26. Tiotropium Respimat Inhaler and the Risk of Death in COPD.

Tiotropium Respimat Inhaler and the Risk of Death in COPD. 23992515 2013 10 17 2013 10 22 2015 11 19 1533-4406 369 16 2013 Oct 17 The New England journal of medicine N. Engl. J. Med. Tiotropium Respimat inhaler and the risk of death in COPD. 1491-501 10.1056/NEJMoa1303342 Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients (...) with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo. In this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 μg or 5 μg, as compared with tiotropium HandiHaler at a once-daily dose of 18 μg. Primary end points were the risk of death (noninferiority

NEJM2013

27. Randomised controlled trial: Tiotropium bromide triple combination therapy improves lung function and decreases asthma exacerbations

Randomised controlled trial: Tiotropium bromide triple combination therapy improves lung function and decreases asthma exacerbations Tiotropium bromide triple combination therapy improves lung function and decreases asthma exacerbations | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Tiotropium bromide triple combination therapy improves lung function and decreases asthma exacerbations Article Text Therapeutics Randomised controlled trial Tiotropium bromide triple combination therapy improves lung function and decreases asthma exacerbations Stephen P

Evidence-Based Medicine (Requires free registration)2013

28. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy Zaniolo O, Iannazzo S, Pradelli L, Miravitlles M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of adding tiotropium bromide to the routine care for chronic obstructive pulmonary disease (COPD). The authors concluded that adding tiotropium to routine care was cost-effective for patients

NHS Economic Evaluation Database.2012

29. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review

Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review Rodrigo GJ, Plaza V, Castro-Rodriguez JA CRD summary This review found (...) that tiotropium plus a long-acting beta 2 agonist, with or without inhaled corticosteroids, appeared to be more effective than tiotropium alone for moderate-to-severe chronic obstructive pulmonary disease, but the data were scarce and follow-ups too short for firm conclusions. Overall, these conclusions appear to be suitably conservative. Authors' objectives To assess the efficacy of three options versus tiotropium monotherapy for maintenance treatment of moderate-to-severe

DARE.2012

30. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness

Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Tiotropium appears to help improve objective lung function test measures, reduce

Health Technology Assessment (HTA) Database.2012

31. Tiotropium for Asthma - Promise and Caution.

Tiotropium for Asthma - Promise and Caution. Tiotropium for asthma--promise and caution. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22938707 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Sep 27;367(13):1257-9. Epub 2012 Sep 2. Tiotropium for asthma--promise and caution. . Comment on [N Engl J Med. 2012] PMID: 22938707 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed

NEJM2012

33. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison 22544891 2012 08 22 2012 10 24 2015 11 19 1468-3296 67 9 2012 Sep Thorax Thorax Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. 781-8 Current guidelines recommend treatment with one or more long-acting (...) bronchodilators for patients with moderate or more severe chronic obstructive pulmonary disease (COPD). The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting β(2) agonist, and the long-acting muscarinic antagonist tiotropium, compared with tiotropium alone. In two identically designed, double-blind, 12-week studies, patients with moderate to severe COPD were randomised to indacaterol 150 μg once daily or matching placebo. All patients concurrently received

EvidenceUpdates2012

34. Randomised controlled trial: Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting ?(2)-agonist remains unclear

Randomised controlled trial: Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting ?(2)-agonist remains unclear Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting β(2)-agonist remains unclear | Evidence-Based Medicine This site uses cookies. By continuing (...) to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Tiotropium is superior to salmeterol in reducing frequency of exacerbations

Evidence-Based Medicine (Requires free registration)2012

35. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium

Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium Hettle R, Wouters H, Ayres J, Gani R, Kelly S, Lion M, Decramer M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of adding tiotropium to usual care, for patients with moderate to very severe chronic obstructive pulmonary disease. The authors concluded that at a willingness-to-pay threshold of £30,000 (or 50,000 Euros) per quality-adjusted life-year gained, adding tiotropium to usual

NHS Economic Evaluation Database.2012

36. Tiotropium in asthma poorly controlled with standard combination therapy.

Tiotropium in asthma poorly controlled with standard combination therapy. 22938706 2012 09 27 2012 10 11 2015 11 19 1533-4406 367 13 2012 Sep 27 The New England journal of medicine N. Engl. J. Med. Tiotropium in asthma poorly controlled with standard combination therapy. 1198-207 Some patients with asthma have frequent exacerbations and persistent airflow obstruction despite treatment with inhaled glucocorticoids and long-acting beta-agonists (LABAs). In two replicate, randomized, controlled (...) trials involving 912 patients with asthma who were receiving inhaled glucocorticoids and LABAs, we compared the effect on lung function and exacerbations of adding tiotropium (a total dose of 5 μg) or placebo, both delivered by a soft-mist inhaler once daily for 48 weeks. All the patients were symptomatic, had a post-bronchodilator forced expiratory volume in 1 second (FEV(1)) of 80% or less of the predicted value, and had a history of at least one severe exacerbation in the previous year

NEJM2012

37. Tiotropium bromide for COPD

Tiotropium bromide for COPD Executive Summary 1 Translation of the executive summary of the final report “Tiotropiumbromid bei COPD” (Version 1.0; Status: 26.06.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports - Commission No. A05-18 Tiotropium bromide for COPD 1 Executive summary of final report A05-18 Version 1.0 Tiotropium bromide for COPD (...) 26.06.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tiotropium bromide for COPD Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal Commission No.: A05-18 Address of publisher: Institute for Quality and Efficiency in Health Care Im Mediapark 8 (KölnTurm) 50670 Cologne Germany Tel.: +49 (0)221 – 35685-0 Fax: +49 (0)221 – 35685-1 E-Mail: berichte@iqwig.de

Institute for Quality and Efficiency in Healthcare (IQWiG)2012

38. [Tiotropium bromide in the treatment of chronic obstructive pulmonary disease]

[Tiotropium bromide in the treatment of chronic obstructive pulmonary disease] Tiotropiumbromid bei COPD [Tiotropium bromide in the treatment of chronic obstructive pulmonary disease] Tiotropiumbromid bei COPD [Tiotropium bromide in the treatment of chronic obstructive pulmonary disease] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation IQWiG. Tiotropiumbromid bei COPD. [Tiotropium bromide in the treatment of chronic obstructive pulmonary disease] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Administration, Inhalation; Bronchodilator Agents; Pulmonary Disease, Chronic Obstructives; Scopolamine Derivatives Language Published German Country of organisation Germany English summary There is no English language

Health Technology Assessment (HTA) Database.2012

39. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial

Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial 21636120 2011 08 02 2011 10 24 2015 11 19 1097-6825 128 2 2011 Aug The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. 308-14 10.1016/j.jaci.2011.04.039 Some patients with severe asthma remain symptomatic and obstructed despite maximal recommended treatment (...) . Tiotropium, a long-acting inhaled anticholinergic agent, might be an effective bronchodilator in such patients. We sought to compare the efficacy and safety of 2 doses of tiotropium (5 and 10 μg daily) administered through the Respimat inhaler with placebo as add-on therapy in patients with uncontrolled severe asthma (Asthma Control Questionnaire score, ≥ 1.5; postbronchodilator FEV₁, ≤ 80% of predicted value) despite maintenance treatment with at least a high-dose inhaled corticosteroid plus a long

EvidenceUpdates2011

40. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. BACKGROUND: Long-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropium are commonly used, either on their own or in combination, for managing persistent symptoms of chronic obstructive pulmonary disease. Patients with severe chronic obstructive pulmonary disease who are symptomatic and who suffer repeated (...) exacerbations are recommended to add inhaled corticosteroids to their bronchodilator treatment. However, the benefits and risks of adding inhaled corticosteroid to tiotropium and long-acting beta(2)-agonists for the treatment of chronic obstructive pulmonary disease are unclear. OBJECTIVES: To assess the relative effects of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists treatment in patients with chronic obstructive pulmonary disease. SEARCH STRATEGY: We searched the Cochrane

Cochrane2011